The initial findings from the large-scale rollout of the world’s first artificial pancreas indicate significant improvements in the management of blood sugar levels for individuals with type 1 diabetes. This rollout, conducted under the National Health Service (NHS) in the UK, has reportedly taken place over the past two years, providing valuable insights into how this technology can enhance the accessibility and effectiveness of diabetes care across diverse communities. Previous deployments of diabetes technologies often resulted in disparities in access, particularly among socioeconomically disadvantaged populations and minority ethnic groups. However, recent data suggests a substantial narrowing of this gap.

As part of the NHS’s ongoing efforts, the artificial pancreas—technically known as a hybrid closed-loop system or automated insulin delivery (AID) system—has been made available to individuals diagnosed with type 1 diabetes. This innovation marks a significant advancement in diabetes management, aiming to provide equitable access to essential healthcare technologies.

Functionality Of The Artificial Pancreas

Unlike traditional continuous glucose monitors (CGMs), which solely track blood sugar levels, an artificial pancreas incorporates interactive functionalities that adjust insulin delivery in real-time based on recorded glucose readings. The system reportedly increases insulin output in response to rising blood glucose levels, while also reducing or halting insulin delivery when those levels fall. This automated response helps maintain blood sugar within an optimal range without the constant need for patients to calculate insulin doses manually, thereby reducing stress, especially during mealtimes and at night.

Clinical trials have demonstrated that these automated systems provide superior management of diabetes compared to CGMs alone. Dr V Mohan, a seasoned diabetologist and researcher, notes that the artificial pancreas essentially serves as an automated insulin delivery system. It continuously sends live blood glucose data to an insulin pump equipped with artificial intelligence, which then autonomously adjusts insulin delivery as required.

This innovative approach primarily caters to individuals with type 1 diabetes, a condition characterised by the immune system’s destruction of insulin-producing cells in the pancreas. Type 1 diabetes patients necessitate lifelong insulin administration. In contrast, type 2 diabetes, which is more prevalent, is typically managed through lifestyle changes, medications, or fewer insulin injections. However, those with type 2 diabetes who require multiple daily insulin injections might also stand to benefit from these automated systems.

Challenges And Implications In India

In India, approximately 9.5 lakh individuals are estimated to be living with type 1 diabetes, with over 3 lakh children and adolescents among them. While AID technology has been introduced in the country, access is notably restricted due to high costs. Currently, the MiniMed 780G from Medtronic is the only commercially available automated insulin delivery system in India, costing around Rs 6.5 lakh. Monthly costs for consumables and insulin can run up to Rs 20,000, making affordability a significant barrier for many patients.

Despite the financial challenges, Dr Mohan reports that several hundred patients in India are successfully using the automated system, illustrating its potential as a breakthrough treatment for type 1 diabetes. Furthermore, he mentions that certain individuals with type 2 diabetes may also experience benefits from the technology if their treatment involves multiple injections daily.

The experience garnered from the NHS rollout presents valuable insights, showcasing that a public health initiative can enhance access to cutting-edge diabetes care across various societal segments. Over the initial two years, the uptake discrepancy between individuals from the least deprived and most deprived backgrounds has reduced to just 3 per cent, with similar advancements noted among minority ethnic groups compared to their white counterparts.

Experts suggest that continuing to develop and implement such systems could revolutionise diabetes management by lowering the incidence of severe blood sugar fluctuations, thereby improving overall quality of life. With ongoing advancements in the technology, automated insulin delivery systems are anticipated to become even more effective in the future.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share